Literature DB >> 26315816

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Antoinette G Nelson1, Xiaoping Zhang2, Usha Ganapathi3, Zoltan Szekely4, Charles W Flexner5, Andrew Owen6, Patrick J Sinko7.   

Abstract

The year 2016 will mark an important milestone - the 35th anniversary of the first reported cases of HIV/AIDS. Antiretroviral Therapy (ART) including Highly Active Antiretroviral Therapy (HAART) drug regimens is widely considered to be one of the greatest achievements in therapeutic drug research having transformed HIV infection into a chronically managed disease. Unfortunately, the lack of widespread preventive measures and the inability to eradicate HIV from infected cells highlight the significant challenges remaining today. Moving forward there are at least three high priority goals for anti-HIV drug delivery (DD) research: (1) to prevent new HIV infections from occurring, (2) to facilitate a functional cure, i.e., when HIV is present but the body controls it without drugs and (3) to eradicate established infection. Pre-exposure Prophylaxis (PrEP) represents a significant step forward in preventing the establishment of chronic HIV infection. However, the ultimate success of PrEP will depend on achieving sustained antiretroviral (ARV) tissue concentrations and will require strict patient adherence to the regimen. While first generation long acting/extended release (LA/ER) DD Systems (DDS) currently in development show considerable promise, significant DD treatment and prevention challenges persist. First, there is a critical need to improve cell specificity through targeting in order to selectively achieve efficacious drug concentrations in HIV reservoir sites to control/eradicate HIV as well as mitigate systemic side effects. In addition, approaches for reducing cellular efflux and metabolism of ARV drugs to prolong effective concentrations in target cells need to be developed. Finally, given the current understanding of HIV pathogenesis, next generation anti-HIV DDS need to address selective DD to the gut mucosa and lymph nodes. The current review focuses on the DDS technologies, critical challenges, opportunities, strategies, and approaches by which novel delivery systems will help iterate towards prevention, functional cure and eventually the eradication of HIV infection.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiretroviral drugs (ARV); Drug delivery targeting; HIV/AIDS; Long-acting/extended-release (LA/ER); Nanomedicine; Nanotechnology; Pre-exposure prophylaxis (PrEP)

Mesh:

Substances:

Year:  2015        PMID: 26315816      PMCID: PMC4879940          DOI: 10.1016/j.jconrel.2015.08.042

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  139 in total

1.  Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines.

Authors:  Naiming Zhou; Zhaowen Luo; Jiansong Luo; Xuejun Fan; Mark Cayabyab; Megumi Hiraoka; Dongxiang Liu; Xiaobing Han; James Pesavento; Chang-Zhi Dong; Youli Wang; Jing An; Hideko Kaji; Joseph G Sodroski; Ziwei Huang
Journal:  J Biol Chem       Date:  2002-03-05       Impact factor: 5.157

2.  Conjugates bearing multiple formyl-methionyl peptides display enhanced binding to but not activation of phagocytic cells.

Authors:  Shahriar Pooyan; Bo Qiu; Marion M Chan; Dunne Fong; Patrick J Sinko; Michael J Leibowitz; Stanley Stein
Journal:  Bioconjug Chem       Date:  2002 Mar-Apr       Impact factor: 4.774

3.  Key Concepts in the Early Immunology of HIV-1 Infection.

Authors:  Basile Siewe; Alan Landay
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

4.  Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique.

Authors:  Jeetendra Singh Negi; Pronobesh Chattopadhyay; Ashok Kumar Sharma; Veerma Ram
Journal:  Eur J Pharm Sci       Date:  2012-11-12       Impact factor: 4.384

5.  In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

Authors:  Christian Callebaut; George Stepan; Yang Tian; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

6.  Synthetic polymers alter the structure of cervical mucus.

Authors:  R K Willits; W M Saltzman
Journal:  Biomaterials       Date:  2001-03       Impact factor: 12.479

Review 7.  Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.

Authors:  Jorge F Senise; Adauto Castelo; Marisol Martínez
Journal:  AIDS Rev       Date:  2011 Oct-Dec       Impact factor: 2.500

8.  Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro.

Authors:  Tathagata Dutta; Hrushikesh B Agashe; Minakshi Garg; Prahlad Balakrishnan; Prahlad Balasubramanium; Madhulika Kabra; Narendra K Jain
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

Review 9.  Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies.

Authors:  S F Assimakopoulos; D Dimitropoulou; M Marangos; C A Gogos
Journal:  Infection       Date:  2014-07-29       Impact factor: 3.553

10.  A temperature-monitoring vaginal ring for measuring adherence.

Authors:  Peter Boyd; Delphine Desjardins; Sandeep Kumar; Susan M Fetherston; Roger Le-Grand; Nathalie Dereuddre-Bosquet; Berglind Helgadóttir; Ásgeir Bjarnason; Manjula Narasimhan; R Karl Malcolm
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

View more
  14 in total

1.  Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.

Authors:  Mahta Samizadeh; Xiaoping Zhang; Simi Gunaseelan; Antoinette G Nelson; Matthew S Palombo; Daniel R Myers; Yashveer Singh; Usha Ganapathi; Zoltan Szekely; Patrick J Sinko
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

Review 2.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

Review 3.  Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Authors:  Yu Gao; John C Kraft; Danni Yu; Rodney J Y Ho
Journal:  Eur J Pharm Biopharm       Date:  2018-04-17       Impact factor: 5.571

4.  Contraception as a Potential Gateway to Pre-Exposure Prophylaxis: US Women's Pre-Exposure Prophylaxis Modality Preferences Align with Their Birth Control Practices.

Authors:  Sarah K Calabrese; Rachel W Galvao; John F Dovidio; Tiara C Willie; Cara B Safon; Clair Kaplan; Abigail Caldwell; Oni Blackstock; Nicole J Phillips; Trace S Kershaw
Journal:  AIDS Patient Care STDS       Date:  2020-03       Impact factor: 5.078

Review 5.  Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.

Authors:  Ioannis Hodges-Mameletzis; Virginia A Fonner; Shona Dalal; Nelly Mugo; Busi Msimanga-Radebe; Rachel Baggaley
Journal:  Drugs       Date:  2019-08       Impact factor: 9.546

6.  Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.

Authors:  Marco Giardiello; Neill J Liptrott; Tom O McDonald; Darren Moss; Marco Siccardi; Phil Martin; Darren Smith; Rohan Gurjar; Steve P Rannard; Andrew Owen
Journal:  Nat Commun       Date:  2016-10-21       Impact factor: 14.919

7.  Antiretroviral resistance in HIV-1 patients at a tertiary medical institute in Saudi Arabia: a retrospective study and analysis.

Authors:  Maha Al-Mozaini; Tahani Alrahbeni; Reem Al-Mograbi; Abdulrahman Alrajhi
Journal:  BMC Infect Dis       Date:  2018-08-28       Impact factor: 3.090

8.  Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations.

Authors:  Faithful Makita-Chingombe; Hilliard L Kutscher; Sara L DiTursi; Gene D Morse; Charles C Maponga
Journal:  J Drug Deliv       Date:  2016-04-17

9.  Aikeqing decreases viral loads in SHIV89.6-infected Chinese rhesus macaques.

Authors:  Gao-Hong Zhang; Jian-Bao Han; Lin Zhu; Rong-Hua Luo; Xi-He Zhang; Xin Chen; Ying-Jie Hu; Lin-Chun Fu; Yong-Tang Zheng
Journal:  Chin Med       Date:  2016-07-01       Impact factor: 5.455

10.  Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood.

Authors:  Sachin Govil; David F Katz
Journal:  Sci Rep       Date:  2019-01-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.